Contract award notice
Results of the procurement procedure
Section I: Contracting
entity
I.1) Name and addresses
The NHS Commissioning Board (Operating under the name of NHS England)
2nd Floor, Rutland House
Runcorn
WA7 2ES
UK
E-mail: philip.grieve@nhs.net
NUTS: UK
Internet address(es)
Main address: https://nhsengland.bravosolution.co.uk
I.2) Joint procurement
The contract is awarded by a central purchasing body
I.4) Type of the contracting authority
Ministry or any other national or federal authority, including their regional or local subdivisions
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
NHS Framework Agreement for the Supply of Recombinant Factor IX Products for the Treatment of Haemophilia B
Reference number: CM/PHS/17/5534
II.1.2) Main CPV code
33141530
II.1.3) Type of contract
Supplies
II.1.4) Short description
NHS National Framework Agreement for the supply of Recombinant Factor IX products for the treatment of Haemophilia B. The framework is intended for use by the Department of Health and Social Care, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland. The framework may also be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1.3.2019 for a period of 24 months until 28.2.2021, with options to extend for a further 24 months. Please refer to the Invitation to Offer documents for the list of purchasing points.
II.1.6) Information about lots
This contract is divided into lots:
No
II.1.7) Total value of the procurement
Value excluding VAT:
192 000 000.00
GBP
II.2) Description
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Please refer to Document No.04d in the ITO for the list of purchasing points.
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of Recombinant Factor IX products for the treatment of Haemophilia B. The framework is intended for use by the Department of Health and Social Care, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland. The framework may also be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1.3.2019 for a period of 24 months until 28.2.2021, with options to extend for a further 24 months. Please refer to the Invitation to Offer documents for the list of purchasing points.
II.2.5) Award criteria
Quality criterion: Price
/ Weighting: 80 %
Quality criterion: Security of Supply
/ Weighting: 5 %
Quality criterion: Ease of Use
/ Weighting: 15 %
Cost criterion: Price
/ Weighting: 80 %
Cost criterion: Security of Supply
/ Weighting: 5 %
Cost criterion: Ease of Use
/ Weighting: 15 %
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.3) Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2018/S 214-489924
Section V: Award of contract
Contract No: CM/PHS/17/5534
Title: NHS Framework Agreement for the Supply of Recombinant Factor 1X Products for the Treatment of Haemophilia B
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
15/02/2019
V.2.2) Information about tenders
Number of tenders received: 5
Number of tenders received from SMEs: 1
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
CSL Behring (UK) Ltd
Haywards Heath
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Contract No: CM/PHS/17/5534
Title: NHS Framework Agreement for the Supply of Recombinant Factor 1X Products for the Treatment of Haemophilia B
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
15/02/2019
V.2.2) Information about tenders
Number of tenders received: 5
Number of tenders received from SMEs: 1
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Novo Nordisk Ltd
Gatwick
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Contract No: CM/PHS/17/5534
Title: NHS Framework Agreement for the Supply of Recombinant Factor 1X Products for the Treatment of Haemophilia B
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
15/02/2019
V.2.2) Information about tenders
Number of tenders received: 5
Number of tenders received from SMEs: 1
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Pfizer Ltd
Tadworth
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Contract No: CM/PHS/17/5534
Title: NHS Framework Agreement for the Supply of Recombinant Factor 1X Products for the Treatment of Haemophilia B
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
15/02/2019
V.2.2) Information about tenders
Number of tenders received: 5
Number of tenders received from SMEs: 1
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Shire Pharmaceuticals Ltd
London
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Contract No: CM/PHS/17/5534
Title: NHS Framework Agreement for the Supply of Recombinant Factor 1X Products for the Treatment of Haemophilia B
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
15/02/2019
V.2.2) Information about tenders
Number of tenders received: 5
Number of tenders received from SMEs: 1
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Swedish Orphan Biovitrum Ltd
Great Abington
UK
NUTS: UK
The contractor is an SME:
Yes
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.3) Additional information
Commercial Medicines Unit Employee.
VI.4) Procedures for review
VI.4.1) Review body
The NHS Commissioning Board (operating under the name of NHS England)
Runcorn
UK
VI.5) Date of dispatch of this notice
06/03/2019